Recent trends in the treatment of cutaneous leishmaniasis

Annals of Saudi Medicine

Volumn 18, Issue 5, 1998, Pages 412-416

  Alkhawajah, Abdulaziz ^a,b  

^a IMAM ABDULRAHMAN BIN FAISAL UNIVERSITY   (Saudi Arabia)

^b Imam Abdulrahman Bin Faisal   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; AMPHOTERICIN B; ANTIMONY DERIVATIVE; CHLOROQUINE; DAPSONE; IMIDAZOLE DERIVATIVE; NIFURTIMOX; PENTAMIDINE; RIFAMPICIN;

ABDOMINAL PAIN; ANAPHYLAXIS; ANEMIA; ANOREXIA; BRADYCARDIA; CARDIOTOXICITY; CAUTERIZATION; CRYOSURGERY; CURETTAGE; DRUG EFFICACY; HEALING; HEAT TREATMENT; HEMOLYTIC ANEMIA; HUMAN; HYPERGLYCEMIA; HYPOKALEMIA; HYPOTENSION; JOINT STIFFNESS; LIVER TOXICITY; MALAISE; MYALGIA; NAUSEA; NEPHROTOXICITY; PANCREATITIS; PRIORITY JOURNAL; QT INTERVAL; REVIEW; SKIN LEISHMANIASIS; THROMBOPHLEBITIS; VOMITING;

EID: 0032437754     PISSN: 02564947     EISSN: None     Source Type: Journal    
DOI: 10.5144/0256-4947.1998.412     Document Type: Review

References (69)

1. World Health Organization (WHO) Report of Expert Committee. The leishmaniases: World Health Organization Technical Report Series 701, World Health Organization, Geneva 1984.
2. Peters W, Al-Zahrani MA. The leishmaniases: a public health problem in Saudi Arabia. Saudi Med J 1987;8:333-43.
3. World Health Organization. WHO Report of the Workshop of Chemotherapy of Old World Cutaneous Leishmaniasis. TDR/LEISH/ CL-JER/83.3. World Health Organization, February 1983.
4. Kubba R, Al-Gindan Y. Leishmaniasis. Dermatol Clin 1989;7:331-51
5. Bryceson ADM. Tropical dermatology. Br J Dermatol 1976;94:223-6.
6. Stratigos JD. New aspects on cutaneous leishmaniasis. Dermatosen 1980;5:139-48.
7. Kikuth W, Schmidt H. Contribution to the progress of antimony therapy of Kala-azar. Chinese Med J 1937;52:425-32.
8. Durand P, Benmussa S, Caruana M. Traitement du Kala-azar par un nouveau campose stibie: 2, 168 RP (premiers resultats). Bull Mem Soc Med Bop Paris 1946;62:399-409.
9. British Pharmacopeia. HMSO, London 1973;439-40.
10. Voller A, Shaw JJ, Bryant C. The effects of two antimony drugs on the in vitro metabolism of radioactive glucose forms of Leishmania tropica. Ann Trop Med Parasitol 1963;57:404-8.
11. Berman JD, Waddell D, Hanson BC. Biochemical mechanisms of the antileishmanial activity of sodium stibogluconate. Antimicrob Agents Chemother 1985;27:916-20.
12. Berman JD, Wyler DJ. An in vitro model for investigation of chemotherapeutic agents in leishmaniasis. J Infec Dis 1980;142:83-6.
13. Hashemi-Nasab A, Zadeh-Shrazi H. Visceral leishmaniasis (kala azar) in Fars province, Iran: study of 130 cases. J Trop Med Hyg 1980;83:119-22.
14. Navin T, Arana BA, Arana FE, Berman JD, Chajon JF. Placebo-controlled clinical trial of sodium stibogluconate (pentostam) versus ketoconazole for treating cutaneous leishmanisis in Guatemala. J Infec Dis 1992;165:528-34.
15. Walto BC, Paulson JE, Arjona MA, Peterson CA. American cutaneous leishmaniasis: inefficacy of metronidazole in treatment. JAMA 1974;228:1256-8.
16. Kern F, Pederson JK. Leishmaniasis in the United States: a report of ten cases in military personnel. JAMA 1973;226:872-4.
17. Ghosh S. Evaluation of sodium stibogluconate in the treatment of cutaneous leishmainasis in Syria. Curr Med Res Opin 1979;6:280-3.
18. Chulay JD, Spencer HG, Mugambi M. Electrocardiographic changes during treatment of leishmaniasis with pentavalent antimony (sodium stibogluconate). Am J Trop Med Hyg 1985;34;702-9.
19. Ballou WR, McChain JR, Gardon DM, Shanks GD, Andujar J, Berman JD, et al. Safety and efficacy of high-dose sodium stibogluconate therapy of American cutaneous leishmaniasis. Lancet 1987;2:13-6.
20. Alkhawaja AM, Larbi E. Al-Gindan Y, Abahussein A, Jain S. Treatment of cutaneous leishmaniasis with antimony: intramuscular vs intralesional administration. Ann Trop Med Parasitol 1997;91:899-905.
21. Bryceson ADM, Chulay JD, Mugambi M, Were JB, Gachihi G, Chunge CN, et al. Visceral leishmaniasis unresponsive to antimonial drugs II: response to high-dose sodium stibogluconate or prolonged treatment with pentamidine. Trans Roy Soc Trop Med Hyg 1985;79:705-14.
22. Marsden PD, Sampaio RNR, Carvalho EM, Veiga JPT, Costa JLM, Lianos-Cuentas EA. High continuous antimony therapy in two patients with unresponsive mucocutaneous leishmaniasis. Am J Trop Med Hyg 1985;34:710-3.
23. Oster CN, Chulay JD, Hendricks LD, McGarvy PB, Takafuji EJ, Pamplan CL, et al. American cutaneous leishmaniasis: a comparison of three sodium stibogluconate treatment schedules. Am J Trop Med Hyg 1985;34:856-60.
24. World Health Organization. Antimonials. Large scale failure in leishmaniasis "alarming." TDR news 1990:34.
25. Hentzer B, Kobayasi T. The ultrastructural changes of Leishmania tropica after treatment with pentamidine. Ann Trop Med Para 1977;71:157-66.
26. Bryceson AD. Diffuse cutaneous leishmaniasis: treatment. Trans Roy Soc Trop Med Hyg 1970;64:369-79.
27. Sen Gupta PC. Chemotherapy of leishmanial discases: a resume of recent researches. Ind Med Gazette 1953;88:20-35.
28. Bryceson ADM. Pentamidine-induced diabetes mellitus. East Afr Med J 1968;45:110-7.
29. Kubba R, Al-Gindan Y, El-Hassan AM, Omer AHS. Ketoconazole in cutaneous leishmaniasis: results of a pilot study. Saudi Med J 1986;7:596-604.
30. Berman JD, Human leishmaniasis: clinical, diagnostic, and chemotherapeutic developments in the last 10 years. Clin Infect Dis 1997;24:684-703.
31. Weinrauch L, Livshin R, El-Ow J. Cutaneous leishmaniasis treatment with ketoconazole. Cutis 1983;32:288-9.
32. Urcuyo FG, Zaias N. Oral ketoconazole in the treatment of leishmaniasis. Int J Dermatol 1982;21:414-6.
33. Jollife DS. Cutaneous leishmaniasis from Belize: treatment with ketoconazole. Clin Exp Dermatol 1986;11:62-8.
34. Abahusein A, Larbi EB, Al-Khawajah A, Al-Gindan Y, Jain S. Evaluation of topical ketoconazole in CL. East Afr Med J 1992;69:14-9.
35. Macnair AL, Gascoigne E, Heap J. Hepatitis and ketoconazole therapy. Br Med J 1981;283:1058-60.
36. Van den Enden E, Campel A, Stevens A. Treatment of cutaneous leishmaniasis with oral itraconazole. Int J Dermatol 1994;33:285-6.
37. Pearson JK, Sawick S. Metronidazole therapy for cutaneous leishmaniasis. Arch Dermatol 1975;111:1343-4.
38. Beltran HF, Gutierrez FM, Biagi FF. Treatment of Mexican cutaneous leishmaniasis with metronidazole. Bull Soc Pathol Exot 1967;70:61.
39. Belehu A, Naffs B, Touw-Langendijk E. Failure of metronidazole treatment in Ethiopian mucocutaneous leishmaniasis. Br J Dermatol 1978;99:421-2.
40. Bryceson ADM. Leishmaniasis. In: Wyngaarden JB, Smith Jr LH, editors. Cecil Textbook of Medicine. Edinburgh: Churchill Living-stone, 1980;815-8.
41. Maegrath B. Clinical tropical diseases. 7th edition. London: Blackwell Scientific Publications, 1980;12:184.
42. Ganor S. The treatment of leishmaniasis residuals with local injections of amphotericin B. Dermatol Int 1967;6:141-3.
43. Martinez S, Marr JJ. Allopurinol in the treatment of American cutaneous leishmaniasis. N Engl J Med 1992;326:741-4.
44. Selim MM, Kandil E. Rifampicin in the treatment of cutaneous leishmaniasis. J Kuwait Med Assoc 1972;6:159.
45. Dogra J, Bhupender BL, Shyam NN. Dapsone in the treatment of cutaneous leishmaniasis. Int J Dermatol 1986;25:398-400.
46. Wyler DJ, Marsden PD. Leishmaniasis. In: Warren KS, Mahmoud AAF, editors. Tropical and Geographical Medicine. New York: McGraw-Hill Book Co., 1984:270-80.
47. Guena MFV, Marsden PD, Cuba CC, Barreto AC. Further trials of nifurtimox in mucocutaneous leishmaniasis. Trans Roy Soc Trop Med Hyg 1981;75:335.
48. Hoare CA. Early discoveries regarding the parasites of Oriental sore. Trans Roy Soc Trop Med Hyg 1938;32: 67-92.
49. Currie MA. Treatment of cutaneous leishmaniasis by curretage. Br Med J 1983;287:1105-6.
50. Azab AS, Kamal MS, El-Hagar MS, Metawaa BA, Hindway DS. Early surgical treatment of cutaneous leishmaniasis. J Dermatol Surg Oncol 1983;9:1007-12.
51. Griffiths WAD, Croft SL. Cutaneous leishmaniasis. Postgrad Doctor Mid East 1980;3:388-94.
52. Berman JD, Nera FK. Effect of temperature on multiplication of leishmania amastigotes within human monocyte-derived macrophages in vitro. Am J Trop Med Hyg 1981;149:302-18.
53. Junaid AJN. Treatment of cutaneous leishmaniasis with infra-red heat. Int J Dermatol 1986;25:470-2.
54. Mutinga MJ, Mingola EN. Alternate treatment of cutaneous leishmaniasis. East Afr Med J 1974;51:68-8.
55. Bassiony A, El-Mashad M, Talaat M, Kutty K, Metaawa B. Cryotherapy in cutaneous leishmaniasis. Br J Dermatol 1982;107:467-74.
56. Al-Gindan Y, Kubba R, El-Hassan AM, Omar AHS, Kutty NK, Saeed MB. Dissemination in cutaneous leishmaniasis 3: lymph node involvement. Int J Dermatol 1989;28:248-54.
57. Sharquie KE, Al-Talib KKA, Chu AC. Intralesional therapy of cutaneous leishmaniasis with sodium stibogluconate antimony. Br J Dermatoll 1988;119:53-7.
58. Kellum RE. Treatment of cutaneous leishmaniasis with an intralesional antimony drug (Pentostam). J Am Acad Dermatol 1986;15:620-2.
59. Al-Qubati Y. Cutaneous leishmaniasis from Yemen: treatment with intralesional injection of sodium stibogluconate with local anesthetic. Saudi Med J 1997;18:433-4.
60. Brenner S. Topical treatment with imidazoles for cutaneous leishmaniasis. Isr J Med Sci 1985;15:620-2.
61. Larbi EM, Alkhawajah AM, Al-Gindan Y, Jain S, Abahusain A, Al-Zayer A. A randomized, double-blind clinical trial of topical clotrimazole versus miconazole for treatment of cutaneous leishmaniasis in the Eastern Province of Saudi Arabia. Am J Trop Med Hyg 1995;52:166-8.
62. El-On J, Jacobos GP, Weinrauch L. Topical chemotherapy of cutaneous leishmaniasis. Parasitol Today 1988;4:76-81.
63. El-On J, Messer G. Leishmania major: antileishmanial activity of methylbenzethonium chloride. Am J Trop Med Hyg 1986;35:1110-6.
64. El-Safi SH, Murphy AG, Bryceson ADM, Neal RA. A double-blind clinical trial of the treatment of cutaneous leishmaniasis with paromomycin ointment. Trans Roy Soc Trop Med Hyg 1990;84:690-1.
65. Pareek SS. Combination of sodium stibogluconate and rifampicin in cutaneous leishmaniasis. Int J Dermatol 1984;23:70-1.
66. Livshin R, El-On J, Weinrauch CL, Even-Paz Z. Therapeutic effect of rifampicin and isoniazid against L. major. Int J Dermatol 1983;22:61.
67. Jacinto C, Pedro L, Castellanos A. Immunotherapy versus chemotherapy in localised cutaneous leishmaniasis. Lancet 1987;l:401-4.
68. Seaman J. Open field trial of short course of liposomal amphotericin B in complicated visceral leishmaniasis. Am J Trop Med Hyg 1993;49:274-7.
69. Squires KA. Immunochemotherapy for visceral leishmaniasis: a controlled pilot trial of antimony versus antimony plus Interferon gamma. Am J Trop Med Hyg 1993;666-9.